Bazil C W
Comprehensive Epilepsy Center, Columbia University College of Physicians and Surgeons, 710 West 168th Street, New York, NY 10032, USA.
Curr Neurol Neurosci Rep. 2001 Jul;1(4):369-75. doi: 10.1007/s11910-001-0092-9.
Finding a niche for each antiepileptic drug has become challenging as more new agents are approved. In this article, the most recent information regarding these drugs is reported, with emphasis on the agents approved in the past 10 years. The evidence clearly shows that, despite limited Food and Drug Administration indications, all drugs are useful in monotherapy, and many have broader spectrums of action. Adverse effects can also help distinguish between agents. Familiarity with this latest information will help clinicians make the best choice for each of their patients with epilepsy.
随着越来越多的新型抗癫痫药物获批,为每种抗癫痫药物找到合适的定位变得颇具挑战性。在本文中,我们报告了有关这些药物的最新信息,重点是过去10年获批的药物。证据清楚地表明,尽管美国食品药品监督管理局(FDA)的适应症有限,但所有药物在单药治疗中都很有用,而且许多药物具有更广泛的作用谱。不良反应也有助于区分不同药物。熟悉这些最新信息将有助于临床医生为每位癫痫患者做出最佳选择。